ArticleBreast cancer research : BCR2023

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

M C Liefaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.